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651Abstract
The American College of Cardiology Foundation
(ACCF), in partnership with key specialty and subspecialty
societies, conducted a review of common clinical scenarios
where noninvasive vascular testing (venous ultrasound and
physiological testing) is frequently considered. The indi-
cations (clinical scenarios) were derived from common
applications or anticipated uses, as well as from current
clinical practice guidelines and results of studies examining
the implementation of the original appropriate use criteria
(AUC). The 116 indications in this document were
developed by a diverse writing group and scored by
a separate independent technical panel on a scale of 1 to 9,
to designate appropriate use (A) (median 7 to 9), maybe
appropriate use (M) (median 4 to 6), and rarely appropriate
use (R) (median 1 to 3).
Preface
In an effort to respond to the need for the rational use of
imaging services in the delivery of high-quality care, the
American College of Cardiology Foundation (ACCF) has
undertaken a process to determine the appropriate use of
cardiovascular imaging for selected patient indications.
Appropriate use criteria (AUC) publications reﬂect an
ongoing effort by the ACCF to critically and systematically
create, review, and categorize clinical situations where
diagnostic tests and procedures are utilized by physicians
caring for patients with cardiovascular diseases. The process
is based on current understanding of the technical capabil-
ities of the imaging modalities examined. Although
impossible to be entirely comprehensive given the wide
diversity of clinical disease, the indications are meant to
identify common scenarios encompassing the majority of
situations encountered in contemporary practice. Given the
breadth of information they convey, the indications do not
directly correspond to the Ninth Revision of the Interna-
tional Classiﬁcation of Diseases (ICD-9) system, as these
codes do not include clinical information, such as symptom
status.
The ACCF believes that careful blending of a broad
range of clinical experiences and available evidence-based
information will help guide a more efﬁcient and equi-
table allocation of healthcare resources in cardiovascular
imaging. The ultimate objective of AUC is to improve
patient care and health outcomes in a cost-effective
manner, but it is not intended to ignore ambiguity and
nuance intrinsic to clinical decision making. AUC thus
should not be considered substitutes for sound clinical
judgment and practice experience.
We are grateful to the technical panel, a professional
group with a wide range of skills and insights, for their
thoughtful and thorough deliberation of the merits of
peripheral vascular ultrasound for various indications. Wewould also like to thank the individuals who provided
a careful review of the draft of indications, the parent AUC
Task Force, and the ACC staff, Z. Jenissa Haidari and
Joseph Allen, for their exceptionally skilled support in the
generation of this document.
Heather L. Gornik, MD, FACC, FAHA
Chair, Testing for Venous Disease and Evaluation of
Hemodialysis Access
Michael J. Wolk, MD, MACC
Chair, Appropriate Use Criteria Task Force1. Introduction
Improvements in cardiovascular imaging technology and
their application, coupled with increasing therapeutic
options for cardiovascular disease, have led to an increase
in cardiovascular imaging. Diagnostic imaging services
reimbursed under Medicare’s physician fee schedule grew
more rapidly than any other type of physician service from
1999 to 2003, although more recently, the rate of imaging
volume growth in Medicare has been slowing. Still, the
armamentarium of noninvasive diagnostic tools has
expanded greatly, offering a variety of new and more
sophisticated imaging techniques. As imaging technology
and clinical applications continue to advance, the health-
care community needs to understand how to best incor-
porate these technologies into daily clinical care and how
to choose between new and long-standing established
imaging technologies. In an effort to respond to this need
and to ensure the effective use of advanced diagnostic
imaging tools, the Appropriate Use Criteria (AUC)
project was initiated. This document serves as the second
in a 2-part series evaluating noninvasive testing for
peripheral vascular disorders with ultrasound and physio-
logical testing. The focus of this document is clinical
indications associated with evaluation of the venous
system as well as preparation for and evaluation of dialysis
access (e.g., arteriovenous ﬁstulas). Appropriate use
criteria for evaluation of peripheral arterial disorders
(carotid, lower and upper extremities, abdominal aorta,
visceral artery) have been previously published (1). The
indications and ﬁndings from this AUC process are meant
to help inform and ensure the highest quality and most
efﬁcient use of vascular laboratory testing (vascular ultra-
sound and physiological testing) in the evaluation of the
venous system.
2. Methods
The indications included in this publication cover
a wide array of cardiovascular signs and symptoms as
well as clinical judgments as to the likelihood of car-
diovascular ﬁndings. Within each main disease category,
*Negative consequences include the risks of the procedure (i.e., radiation or contrast
exposure) and the downstream impact of poor test performance such as delay in
diagnosis (false negatives) or inappropriate diagnosis (false positives).
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majority of clinical scenarios without making the list of
indications excessive. During the development of this
document, the AUC Task Force revised the terminology
and deﬁnitions to better clarify the appropriateness
categories to avoid misinterpretation and misuse of
appropriate use criteria documents (2).
The indications were constructed by experts in periph-
eral vascular disease and in other ﬁelds and were modiﬁed
on the basis of discussions among the task force and
feedback from independent reviewers and the technical
panel. Wherever possible, indications were mapped to
relevant clinical guidelines and key publications/references
where available in the medical literature (Online
Appendix).
Indication Development
The indications were constructed by a writing group with
expertise in both the science and clinical practice of
vascular ultrasound and physiological testing, vascular
medicine and vascular surgery, and vascular imaging and
intervention. The writing group was tasked with devel-
oping a list of clinical scenarios covering the majority of
patients that clinicians might consider referring for
noninvasive ultrasound and physiological testing. The term
“indication” is used interchangeably with “clinical scenario”
in the document for brevity and does not imply that
a procedure should necessarily be performed. Indication
modiﬁcations were made through discussions with the
American College of Cardiology Foundation (ACCF)
AUC Task Force and feedback from reviewers that include
additional experts in the areas noted in the previous text.
The current document includes indications related to
noninvasive vascular testing for venous disease and for
hemodialysis access. Appropriate use criteria for the
evaluation of arterial disorders have been previously
published (1).
Rating Process and Scoring
The technical panel ﬁrst rated the indications indepen-
dently. The technical panel then convened for a face-to-
face meeting to discuss each indication. At this meeting,
panelists were provided with their scores and a blinded
summary of their peers’ scores. After the meeting,
panelists once again independently rated each indication
according to the originally published classiﬁcation terms to
indicate their ﬁnal scores. The technical panel then
completed an additional third rating process to address
a few areas that required further clariﬁcation and to
incorporate the revised indication classiﬁcation termi-
nology (2). During this ﬁnal rating, the technical panel was
asked to reexamine the indications using the new terms and
expanded deﬁnitions, realizing that the use of new terms
could result in some reclassiﬁcation of the clinical
scenarios.When rating each clinical scenario, the technical panel
was asked to assess whether ultrasound and/or physiolog-
ical testing was appropriate, maybe appropriate, or rarely
appropriate, according to the following deﬁnition of
appropriate use:
An appropriate imaging study is one in which the ex-
pected incremental information, combined with clinical
judgment, exceeds the expected negative consequence* by
a sufﬁciently wide margin for a speciﬁc indication that the
procedure is generally considered acceptable care and
a reasonable approach for the indication.
The technical panel scored each indication as follows:
Median Score 7 to 9: Appropriate Care
An appropriate option for management of this patient
population due to beneﬁts generally outweighing
risks; effective option for individual care plans, although
not always necessary depending on physician judgment
and patient-speciﬁc preferences (i.e., procedure is
generally acceptable and is generally reasonable for the
indication).
Median Score 4 to 6: Maybe Appropriate Care
At times an appropriate option for management of this
patient population due to variable evidence or agreement
regarding the beneﬁts/risks ratio, potential beneﬁt based
on practice experience in the absence of evidence, and/or
variability in the population; effectiveness for individual
care must be determined by a patient’s physician in con-
sultation with the patient based on additional clinical
variables and judgment along with patient preferences (i.e.,
procedure may be acceptable and may be reasonable for the
indication).
Median Score 1 to 3: Rarely Appropriate Care
Rarely an appropriate option for management of this
patient population due to the lack of a clear beneﬁt/risk
advantage; rarely an effective option for individual care
plans; exceptions should have documentation of the clinical
reasons for proceeding with this care option (i.e., procedure
is not generally acceptable and is not generally reasonable
for the indication).
The division of these scores into 3 levels of appropri-
ateness is somewhat arbitrary, and the numeric designa-
tions should be viewed as a continuum. Further, there is
diversity in clinical opinion for particular clinical scenarios,
such that scores in the intermediate level of appropriate use
should be labeled “maybe appropriate,” because critical
patient or research data may be lacking or discordant. This
JACC Vol. 62, No. 7, 2013 Gornik et al.
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653designation should be a prompt to the ﬁeld to carry out
deﬁnitive research investigations whenever possible. It is
anticipated that the AUC reports will continue to be
revised as further data are generated and information from
the implementation of the criteria is accumulated.
To prevent bias in the scoring process, the technical
panel was deliberately composed of a minority of
specialists in vascular noninvasive testing. In addition, care
was taken in providing objective, nonbiased information,
including guidelines and key references, to the technical
panel.
The level of agreement among panelists as deﬁned by
RAND (3) was analyzed based on the BIOMED rule for
a panel of 14 to 16 members. As such, agreement was
deﬁned as an indication where 4 or fewer panelists’ ratings
fell outside the 3-point region containing the median
score.
Disagreement was deﬁned as where at least 5 panelists’
ratings fell in both the appropriate and the rare appropriate
categories. Any indication having disagreement was cate-
gorized as maybe appropriate regardless of the ﬁnal
median score. Indications that met neither deﬁnition for
agreement or disagreement are in a third, unlabeled
category.
3. Assumptions
To prevent any inconsistencies in interpretation, speciﬁc
assumptions are provided that were considered by the
technical panel in rating the relevant clinical indications for
the appropriate use of peripheral vascular ultrasound and
physiological testing:
1. Clinical indications assume that a history and
physical examination has been performed by a
qualiﬁed healthcare provider before performance of
the vascular ultrasound or physiological testing
examination.
2. A peripheral vascular ultrasound and physiological
testing examination and report will include
performance of the vascular ultrasound or physio-
logical testing examination using a standardized
scanning protocol and standardized documenta-
tion of gray scale (B-mode), color ﬂow, and spectral
Doppler wave form images as required for the
speciﬁc test type. Scanning protocols may be devel-
oped by the laboratory based upon laboratory-
speciﬁc considerations and techniques as well as
recommended technical elements per appropriate
organizations (e.g., American Institute of Ultra-
sound inMedicine, Society for Vascular Ultrasound)
or laboratory accrediting organizations (Intersocietal
Accreditation Commission [IAC] or American
College of Radiology (ACR)) (4).
3. Interpretation of the vascular ultrasound or phy-
siological testing examination by a physicianinterpreter using standard, laboratory-speciﬁc
diagnostic criteria that have been developed by
the laboratory or adapted from the ultrasound
literature and are validated internally for accuracy as
part of ongoing quality assurance programs. It is
implicit that diagnostic criteria will vary across
laboratories, but adherence to pre-deﬁned criteria
within a laboratory is required. Laboratory-speciﬁc
protocols should be compiled in written policy
and procedure manuals that are made available
to medical and technical staff for review and
discussion.
4. Appropriate equipment is used for each speciﬁc
type of testing, including appropriate frequency
ultrasound transducers and properly sized cuffs and
others sensors for physiological testing.
5. Documentation that the vascular sonographer
used optimal angle correction techniques to
ensure accurate angle of insonation for reporting
of Doppler velocity measurements. In general, an
angle of insonation of 60 or less is used with
appropriate sample volume placement.
6. All standard vascular ultrasound and physiological
testing techniques have a sensitivity and speciﬁcity
similar to those found in the published literature for
the speciﬁc examination type.
7. Testing should be performed by a credentialed
technologist (registered vascular technologist
[RVT] or registered vascular sonographer [RVS])
and interpreted by a credentialed physician (regis-
tered physician in vascular interpretation [RPVI]).
Finally, the testing should be done in a facility
accredited in vascular testing (e.g., IAC–Vascular
Testing or ACR).
8. If prior testing is of poor technical quality, repeat
imaging may sometimes be appropriate in
a different facility or after the conditions that
restricted the prior testing are no longer present
(e.g., bowel gas, open wounds) prior to the speci-
ﬁed timeframes.
9. The appropriate use of testing is assumed to have
the potential to impact clinical decision making and
to direct therapeutic interventions.
10. The range of potential indications for vascular
ultrasound and physiological testing is quite large,
particularly in comparison with other cardiovas-
cular imaging tests. Thus, the indications are, at
times, purposefully broad to cover an array of
vascular signs and symptoms as well as the
ordering physician’s best judgment as to the
presence of vascular abnormalities. Additionally,
there are likely clinical scenarios that are not
covered by the current indications in this
document.
11. Venous duplex examinations that are performed to
assess for suspected venous thrombosis in the limbs
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compression maneuvers in addition to color ﬂow
and spectral Doppler examination.
12. Complete vascular examinations (ultrasound and
physiological testing) require bilateral studies in the
majority of clinical cases, though speciﬁc clinical
indications may warrant a unilateral or limited
study, (e.g., unilateral leg pain and swelling and
suspected lower extremity deep vein thrombosis).
The decision to perform a complete bilateral or
unilateral examination should be determined by the
study indications and the standardized laboratory
scanning protocol.
13. When a unilateral venous examination is per-
formed, a spectral Doppler waveform from
a contralateral proximal deep vein (e.g., subclavian
or internal jugular vein for the upper extremities or
common femoral vein for the lower extremities)
should be recorded to allow for comparative
assessment of ﬂow patterns in the limbs.
14. For the clinical scenarios presented in the section
on Hemodialysis Vascular Access Duplex Ultra-
sound (Table 8) it is acknowledged that the
appropriate vascular laboratory assessment might
include more than duplex ultrasound of the
extremity veins. Depending on the scenario, addi-
tional testing could include arterial duplex scanning
and physiological tests such as segmental limb
pressures and digit pressure measurements.
15. To optimize patient care and minimize need for
unnecessary repeat studies, it is generally recom-
mended that repeat or serial scans (e.g., for
surveillance of calf vein thrombosis with contrain-
dication to anticoagulation) be performed in the
same facility.
16. Raters were instructed to consider cost implicitly
when making the appropriate use determination.
17. Raters were instructed to consider patient safety
implicitly in the appropriate use determination.
18. If the reason for a test can be assigned to more than
1 clinical indication, it should be matched to the
indication with the highest appropriate use score.
19. For each indication, the rating should reﬂect
whether the test is reasonable for the patient
according to the appropriate use deﬁnition, not
whether the test is better or worse than another
modality.
20. The category of “maybe appropriate” should be
used when insufﬁcient clinical data are available for
a deﬁnitive categorization or there is disagreement
as deﬁned in the methods. The designation of
“maybe appropriate” is assumed to not provide
grounds for denial of reimbursement.
21. Unless explicitly stated, the indications in
this document indicate only whether vascularultrasound or physiological testing by itself is
reasonable. The indications do not address
whether it is reasonable to perform vascular ul-
trasound or physiological testing instead of or in
conjunction with another test, either before or
after the test.
4. Deﬁnitions
1. Physiological testing:
Evaluation of the peripheral venous circulation
based on measurement of limb blood ﬂow using
plethysmographic sensors (e.g., air, strain gauge, or
photoplethysmography) with physiological maneu-
vers (e.g., limb positioning, limb exercise, tourni-
quet application), or other parameters, without
utilizing data from direct imaging of the blood
vessels.
2. Screening examination:
Testing conducted to determine the presence or
absence of disease in an asymptomatic patient.
3. Surveillance examination:
Testing conducted to monitor disease progression
based solely on the passage of time since initial
diagnosis or revascularization (e.g., calf vein throm-
bosis with contraindication to anticoagulation). It is
assumed that baseline testing has already been
conducted.
5. Abbreviations
ACR ¼ American College of Radiology
AVF ¼ autogenous arteriovenous ﬁstula (including venous
transpositions)
AVG ¼ prosthetic arteriovenous graft
CHF ¼ congestive heart failure
DVT ¼ deep vein thrombosis
IAC ¼ Intersocietal Accreditation Commission
ICU ¼ intensive care unit
IVC ¼ inferior vena cava
RPVI ¼ registered physician in vascular interpretation
RVT [ registered vascular technologist
RVS [ registered vascular sonographer
TIPS ¼ transjugular intrahepatic portosystemic shunt6. Peripheral Vascular Ultrasound and
Physiological Testing Part II: Testing for
Venous Disease and Evaluation of
Hemodialysis Access Appropriate Use
Criteria (by Indication)
Section 1: Upper Extremity Venous
Duplex Ultrasound
Table 1. Venous Duplex of the Upper Extremities for Patency and Thrombosis
Indication
Appropriate
Use Rating
Limb Swelling
1.  Unilateraldacute A (9)
2.  Unilateraldchronic, persistent A (7)
3.  Bilateraldacute
 Suspected central venous obstruction
A (8)
4.  Bilateraldchronic, persistent
 No alternative diagnosis identiﬁed (e.g., no CHF or anasarca from hypoalbuminemia)
 Suspected central venous obstruction
A (7)
Limb Pain (Without Swelling)
5.  Nonarticular pain in the upper extremity (no indwelling upper extremity venous catheter) M (5)
6.  Nonarticular pain in the upper extremity with indwelling upper extremity venous catheter A (7)
7.  Tender, palpable cord in the upper extremity A (8)
Shortness of Breath
8.  Suspected pulmonary embolus (no indwelling upper extremity venous catheter) M (4)
9.  Suspected pulmonary embolus with indwelling upper extremity venous catheter M (6)
10.  Diagnosed pulmonary embolus (no indwelling upper extremity venous catheter) M (4)
11.  Diagnosed pulmonary embolus with indwelling upper extremity venous catheter M (6)
Fever
12.  Fever of unknown origin (no indwelling upper extremity venous catheter) R (2)
13.  Fever with indwelling upper extremity venous catheter M (4)
Known Upper Extremity Venous Thrombosis
14.  New upper extremity pain or swelling while on anticoagulation A (7)
15.  New upper extremity pain or swelling, not on anticoagulation (i.e., contraindication to anticoagulation) A (7)
16.  Before anticipated discontinuation of anticoagulation treatment M (5)
17.  Shortness of breath in a patient with known upper extremity DVT R (3)
18.  Surveillance after diagnosis of upper extremity superﬁcial phlebitis
 Not on anticoagulation, phlebitis location 5 cm from deep vein junction
M (6)
19.  Surveillance after diagnosis of upper extremity superﬁcial phlebitis
 Not on anticoagulation, phlebitis location 5 cm from deep vein junction
M (4)
Vein Mapping Prior to Bypass Surgery (Coronary or Peripheral)
20.  In the absence of adequate leg vein for harvest A (8)
21.  In the presence of adequate leg vein for harvest M (4)
Screening Examination for Upper Extremity DVT*
22.  Prior to pacemaker or implantable cardiac deﬁbrillator placement R (3)
23.  Prolonged ICU stay (e.g., >4 days)
 No indwelling upper extremity venous catheter
R (2)
24.  Prolonged ICU stay (e.g., >4 days) with indwelling upper extremity venous catheter R (3)
25.  Monitoring indwelling upper extremity venous catheter that is functional R (2)
26.  In those with high risk: acquired, inherited, or hypercoagulable state R (2)
27.  Positive D-dimer test in a hospital inpatient R (1)
*Screening examination performed in the absence of upper extremity pain or swelling.
A ¼ appropriate; CHF ¼ congestive heart failure; DVT ¼ deep vein thrombosis; ICU ¼ intensive care unit; M ¼ maybe appropriate; R ¼ rarely appropriate.
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Upper extremity venous duplex ultrasound was rated as an
appropriate test in the setting of limb swelling, non-
articular upper extremity pain or palpable cord, and when
new pain or swelling is noted in the presence of known
upper extremity deep vein thrombosis (DVT). It was
deemed rarely appropriate to perform an upper extremity
venous ultrasound for evaluation of fever of unknown
origin in the absence of an indwelling upper extremity
venous catheter or for evaluation of shortness of breath in
a patient with known upper extremity DVT.
Screening for upper extremity DVT in an asymptomatic
patient was rated as rarely appropriate across 6 of 6 clinical
scenarios, including the patient with prolonged intensivecare unit (ICU) stay (with or without an upper extremity
venous catheter), prior to pacemaker or deﬁbrillator
placement, for monitoring of a functional upper extremity
venous catheter, or for upper extremity DVT screening in
those with hypercoagulable state or with positive D-dimer
test.
Upper extremity vein mapping (e.g., of cephalic and
basic veins) prior to coronary or peripheral bypass surgery
was rated as an appropriate test in the absence of adequate
leg vein for harvest and as maybe appropriate in certain
settings when adequate leg vein conduit is present.
Section 2: Lower Extremity Venous
Duplex Ultrasound
Table 2. Venous Duplex of the Lower Extremities for Patency and Thrombosis
Indication
Appropriate
Use Rating
Limb Swelling
28.  Unilateraldacute A (9)
29.  Unilateraldchronic, persistent A (7)
30.  Bilateraldacute A (8)
31.  Bilateraldchronic, persistent
 No alternative diagnosis identiﬁed (e.g., no CHF or anasarca from hypoalbuminemia)
M (6)
Limb Pain (Without Swelling)
32.  Nonarticular pain in the lower extremity (e.g., calf or thigh) A (7)
33.  Knee pain M (4)
34.  Tender, palpable cord in the lower extremity A (8)
Shortness of Breath
35.  Suspected pulmonary embolus A (8)
36.  Diagnosed pulmonary embolus A (7)
Fever
37.  Fever of unknown origin (no indwelling lower extremity venous catheter) M (5)
38.  Fever with indwelling lower extremity venous catheter M (5)
Known Lower Extremity Venous Thrombosis
39.  Surveillance of calf vein thrombosis for proximal propagation in patient with contraindication to anticoagulation
(within 2 weeks of diagnosis)
A (7)
40.  New lower extremity pain or swelling while on anticoagulation A (7)
41.  New lower extremity pain or swelling, not on anticoagulation (i.e., contraindication to anticoagulation) A (8)
42.  Before anticipated discontinuation of anticoagulation treatment M (5)
43.  Shortness of breath in a patient with known lower extremity DVT M (5)
44.  Surveillance after diagnosis of lower extremity superﬁcial phlebitis
 Not on anticoagulation, phlebitis location 5 cm from deep vein junction
A (7)
45.  Surveillance after diagnosis of lower extremity superﬁcial phlebitis
 Not on anticoagulation, phlebitis location 5 cm from deep vein junction
M (5)
Vein Mapping Prior to Bypass Surgery (Coronary or Peripheral)
46.  In the absence of prior lower extremity vein harvest or ablation procedure A (8)
47.  In the presence of prior lower extremity vein harvest or ablation procedure A (8)
Screening Examination for Lower Extremity DVT*
48.  After orthopedic surgery R (3)
49.  Prolonged ICU stay (e.g., >4 days) R (3)
50.  In those with high risk: acquired, inherited, or hypercoagulable state R (3)
51.  Positive D-dimer test in a hospital inpatient R (2)
Post-Endovenous (Great or Small) Saphenous Ablation
52.  Lower extremity swelling or pain A (8)
53.  Routine post-procedural follow-up, no lower extremity pain or swelling Within 10 days post-procedure A (7)
Other Symptoms or Signs of Vascular Disease
54.  Physiological testing positive for venous obstruction A (7)
55.  Patent foramen ovale with suspected paradoxical embolism for patient without lower extremity pain or swelling obstruction A (7)
*Screening examination performed in the absence of lower extremity pain or swelling.
A ¼ appropriate; DVT ¼ deep vein thrombosis; ICU ¼ intensive care unit; M ¼ maybe appropriate; R ¼ rarely appropriate.
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Lower extremity venous duplex ultrasound (Table 2) was
rated an appropriate test in the setting of limb swelling,
nonarticular lower extremity pain or palpable cord,
pulmonary embolism, and when new pain or swelling is
noted in the presence of known lower extremity DVT.
Testing was also rated as appropriate for certain surveillance
indications, namely surveillance of calf vein thrombosis for
proximal extension of DVT when anticoagulation is con-
traindicated and for superﬁcial thrombophlebitis of the legs
(i.e., great or small saphenous vein) located near a deep vein
junction. Venous ultrasound was rated as appropriate for
early procedural follow-up after endovenous saphenousablation procedures (in the patient with or without symp-
toms). Lower extremity venous duplex ultrasound was rated
as appropriate for further evaluation of the patient with
patent foramen ovale with suspected paradoxical embolism
and for the patient with evidence of lower extremity venous
obstruction on venous physiological testing (plethysmog-
raphy) that suggests the possibility of DVT.
Screening for lower extremity DVT with duplex ultra-
sound in an asymptomatic patient was rated as rarely
appropriate across multiple clinical scenarios, including the
patient with a prolonged ICU stay, following orthopedic
surgery, for those with hypercoagulable state, or with
a positive D-dimer test. This was consistent with the rarely
Table 3. Duplex Evaluation for Venous Incompetency
Indication
Appropriate
Use Rating
Venous Insufﬁciency (Venous Duplex With Provocative Maneuvers for Incompetency)
56.  Active venous ulcer A (9)
57.  Healed venous ulcer A (7)
58.  Spider veins (telangiectasias) R (3)
59.  Varicose veins, entirely asymptomatic M (5)
60.  Varicose veins with lower extremity pain or heaviness A (7)
61.  Visible varicose veins with chronic lower extremity swelling or skin changes of chronic venous insufﬁciency (e.g., hyperpigmentation,
lipodermatosclerosis)
A (7)
62.  Skin changes of chronic venous insufﬁciency without visible varicose veins (e.g., hyperpigmentation, lipodermatosclerosis) A (7)
63.  Lower extremity pain or heaviness without signs of venous disease M (5)
64.  Mapping prior to venous ablation procedure A (8)
65.  Prior endovenous (great or small) saphenous ablation procedure with new or worsening varicose veins in the ipsilateral limb A (8)
66.  Prior endovenous (great or small) saphenous ablation procedure with no residual symptoms R (3)
A ¼ appropriate; M ¼ maybe appropriate; R ¼ rarely appropriate.
Table 4. Venous Physiological Testing (Plethysmography) With Provocative Maneuvers to Assess for Patency and/or
Incompetency
Indication
Appropriate
Use Rating
Limb Pain, Swelling, or Other Signs of Venous Disease
67.  Active venous ulcer A (7)
68.  Varicose veins, entirely asymptomatic M (5)
69.  Varicose veins with lower extremity pain or heaviness A (7)
70.  Varicose veins with chronic lower extremity swelling or skin changes of chronic venous insufﬁciency (e.g., hyperpigmentation or
lipodermatosclerosis)
A (7)
71.  Skin changes of chronic venous insufﬁciency without visible varicose veins (e.g., hyperpigmentation or lipodermatosclerosis) A (7)
72.  Lower extremity pain or heaviness without signs of venous disease M (6)
73.  Limb swelling: unilateraldacute
 Suspected acute venous thrombosis
R (3)
Shortness of Breath
74.  Suspected pulmonary embolus R (2)
A ¼ appropriate; M ¼ maybe appropriate; R ¼ rarely appropriate.
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ultrasound discussed in the preceding text.
Lower extremity vein mapping (of the saphenous veins)
prior to coronary or peripheral bypass surgery was rated as
an appropriate test regardless of whether or not the patient
has previously undergone lower extremity vein harvest or
ablation procedure.
Similar to the upper extremities, lower extremity venous
duplex ultrasound for evaluation of fever of unknown
etiology was rated as maybe appropriate in certain clinical
scenarios, though the evidence to support this practice is
limited (5–7).
Duplex ultrasound evaluation for venous incompetency,
with provocative physiological maneuvers such as distal
limb augmentation and/or Valsalva, was rated as appro-
priate in the setting of signiﬁcant clinical symptoms
and signs of venous disease, including: active or healed
venous ulcer, varicosities with lower extremity discom-
fort, swelling, or chronic skin changes (Table 3). Du-
plex ultrasound for venous incompetency was rated as
maybe appropriate for evaluation of the patient with sig-
niﬁcant, though asymptomatic, varicose veins (e.g., large,disﬁguring varicose veins) or for the patient with lower
extremity pain or heaviness without signs of venous
disease.
Duplex ultrasound was rated as rarely appropriate for
evaluation of isolated spider veins (telangiectasias) without
other stigmata of venous disease or for the patient with
prior saphenous vein ablation with no residual symptoms
(although initial follow-up duplex for within the initial 10
days after the procedure was rated as appropriate, see the
preceding text).
Summary: Venous Physiological Testing
Selected clinical indications for venous physiological
testing (plethysmography) with provocative maneuvers
were evaluated. Venous physiological testing was rated as
appropriate in the setting of signiﬁcant clinical symptoms
and signs of chronic venous insufﬁciency, including: active
venous ulcer, symptomatic varicose veins, and chronic skin
changes such as lipodermatosclerosis or hyperpigmenta-
tion. Similar to the indications for venous duplex ultra-
sound for venous incompetency, venous physiological
testing was rated as maybe appropriate for evaluation of the
Table 5. Duplex of the IVC and Iliac Veins for Patency and Thrombosis
Indication Appropriate Use Rating
Prior to IVC Filter Placement
75.  Prior to IVC ﬁlter placement
 For procedural access planning
M (6)
Evaluation for Suspected Deep Vein Thrombosis
76.  Lower extremity swellingdunilateral or bilateraldas a “stand-alone test” without a venous duplex of the
lower extremities
R (3)
77.  Lower extremity swellingdunilateral or bilateraldcombined routinely with a venous duplex of the lower extremities M (4)
78.  Lower extremity swellingdunilateral or bilateraldperformed selectivelydwhen the lower extremity venous duplex
is normal
M (6)
79.  Lower extremity swellingdunilateral or bilateraldperformed selectivelydwhen the lower extremity venous duplex is
positive for acute proximal DVT
A (7)
80.  Selectivelydwhen the ﬂow pattern in 1 or both common femoral veins is abnormal A (8)
Evaluation for Suspected Pulmonary Embolus
81.  Pulmonary symptoms (suspected pulmonary embolus)das a “stand-alone test” without a venous duplex of the
lower extremities
R (2)
82.  Pulmonary symptoms (suspected pulmonary embolus)dcombined routinely with a venous duplex of the
lower extremities
M (4)
Evaluation of Other Symptoms or Signs of Abdominal Vascular Disease
83.  Abdominal pain R (3)
84  Abdominal bruit R (3)
85.  Fever of unknown origin R (3)
A ¼ appropriate; DVT ¼ deep vein thrombosis; IVC ¼ inferior vena cava; M ¼ maybe appropriate; R ¼ rarely appropriate.
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with lower extremity pain or heaviness without signs of
venous disease.
Importantly, venous physiological testing was rated as
rarely appropriate for evaluation of the patient with sus-
pected acute lower extremity DVT or pulmonary embo-
lism. In the case of suspected acute lower extremity DVT,
duplex ultrasound would be the best initial test.
Section 3: Duplex Evaluation of the
Inferior Vena Cava and Iliac VeinsTable 6. Duplex of the Hepatoportal System (Portal Vein, Hepatic V
Inferior Vena Cava) for Patency, Thrombosis, and Flow Direction*
Indication
Evaluation of Hepatic Dysfuncti
86.  Abnormal liver function tests
 No alternative diagnosis identiﬁed (e.g., medication related or infectio
87.  Cirrhosis with or without ascites
88.  Jaundice
 As an initial diagnostic test
89.  Jaundice
 No alternative diagnosis identiﬁed after initial evaluation (e.g., no bilia
90.  Hepatomegaly and/or splenomegaly
91.  Portal hypertension
Surveillance Following Portal D
92.  Follow-up of a TIPS
Evaluation of Other Symptoms or Signs
93.  Abdominal pain
94.  Fever of unknown origin
Evaluation of Cardiac and/or
95.  Pulmonary symptoms (suspected pulmonary embolus)
96.  Cor pulmonale
*Testing indications refer to evaluation of native hepatoportal venous system only (i.e., hepatic transp
A ¼ appropriate; TIPS ¼ transjugular intrahepatic portosystemic shunt; M ¼ maybe appropriate; R ¼Summary: Duplex Evaluation of the Inferior Vena Cava
and Iliac Veins
In the setting of evaluation for suspected DVT, iliocaval
duplex was rarely appropriate as a “stand-alone test,” but
was rated as appropriate or maybe appropriate for use
either routinely or selectively in conjunction with lower
extremity venous duplex scanning (Table 5). Scanning of
the inferior vena cava (IVC) and iliac veins was rated as
appropriate when performed selectively with a positive
lower extremity venous duplex demonstrating proximal
DVT or when an abnormal ﬂow pattern was found in 1 oreins, Splenic Vein, Superior Mesenteric Vein,
Appropriate Use Rating
on or Portal Hypertension
us hepatitis)
M (6)
A (7)
R (3)
ry obstruction)
M (6)
A (7)
A (7)
ecompression Procedure
A (8)
of Abdominal Vascular Disease
M (4)
R (3)
Pulmonary Symptoms
R (3)
R (3)
lant sites and arterial system excluded).
rarely appropriate.
Table 7. Duplex of the Renal Veins for Patency and Thrombosis*
Indication Appropriate Use Rating
Evaluation for Suspected Renal Vein ThrombosisdPotential Signs and/or Symptoms
97.  Gross hematuria R (3)
98.  Acute renal failure M (5)
99.  Acute ﬂank pain M (5)
Evaluation of Cardiac and/or Pulmonary Symptoms
100.  Pulmonary symptoms (suspected pulmonary embolus) R (3)
Evaluation of Other Symptoms or Signs of Abdominal Vascular Disease
101.  Drug-resistant hypertension (suspected renal artery stenosis) R (3)
102.  Microscopic hematuria (prior to urological evaluation) R (2)
103.  Fever of unknown origin R (2)
104.  Epigastric bruit R (2)
*Testing indications refer to evaluation of native renal veins only for patency (i.e., renal transplant sites and renal arteries excluded).
A ¼ appropriate; DVT ¼ deep vein thrombosis; IVC ¼ inferior vena cava; M ¼ maybe appropriate; R ¼ rarely appropriate.
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suspected pulmonary embolism, iliocaval duplex was rated
as rarely appropriate as a “stand-alone test” but as maybe
appropriate when combined routinely with a lower
extremity venous duplex examination in this setting. The
indications of abdominal pain, abdominal bruit, and fever
of unknown origin were all rated as rarely appropriate for
IVC and iliac vein duplex. Duplex ultrasound of the IVC
and iliac veins was rated as maybe appropriate for proce-
dural planning prior to IVC ﬁlter placement.Section 4: Hepatoportal and
Renal Venous Evaluation
Summary: Hepatoportal and Renal Venous
Duplex Ultrasound
Duplex scanning of the hepatoportal system (Table 6) was
rated as appropriate for the evaluation of cirrhosis withoutTable 8. Pre-Operative Planning and Post-Operative Assessment of
Indication
Assessment Prior to Acce
105.  Pre-operative mapping study (upper extremity arterial and venous du
106.  Pre-operative mapping study (upper extremity arterial and venous du
“Failure to M
107.  “Failure to mature” on basis of physical examination 0–6 weeks aft
108.  “Failure to mature” on basis of physical examination >6 weeks afte
Symptoms and Sign
109.  Signs of access site malfunction during dialysis (e.g., low blood ﬂow
venous pressure)
110.  Mass associated with an AVF/AVG
111.  Loss of palpable thrill of AVF/AVG
112.  Arm swelling
113.  Hand pain, pallor, and/or digital ulceration (i.e., evaluation for suspe
114.  Cool extremity
 Without pain, pallor, or ulceration
115.  Difﬁcult cannulation by multiple personnel on multiple attempts
Asymptoma
116.  Routine surveillance of a functioning AVF or AVG
*Ultrasound assessment prior to creation of dialysis access (AVF or AVG) typically includes a combined a
veins (patency, size, and length of conduit), patency of central venous outﬂow, and adequacy of adequate
a history of prior central venous catheter(s). yIn a mature AVF or AVG that is being accessed for hemod
A ¼ appropriate; AVF ¼ autogenous arteriovenous ﬁstula (including venous transpositions); AVG ¼ pascites, hepatomegaly and/or splenomegaly, and portal
hypertension. Duplex scanning was rated as rarely appro-
priate as an initial diagnostic test in patients with jaundice
but maybe appropriate for evaluation of patients with
abnormal liver function tests and jaundice with no alter-
native diagnosis identiﬁed after an initial workup. Follow-
up after a transjugular intrahepatic portosystemic shunt
(TIPS) procedure was rated as appropriate for duplex
scanning. Hepatoportal scanning was rated as maybe
appropriate for abdominal pain and rarely appropriate for
fever of unknown origin and cor pulmonale or pulmonary
symptoms.
Likely reﬂecting the uncommon nature of isolated renal
vein pathology as a cause of genitourinary symptoms or
signs, there were no clinical indications rated as appropriate
for assessment of the native renal veins with duplex
ultrasound (Table 7) in this document. For the indications
of acute renal failure and acute ﬂank pain, symptoms ofa Vascular Access Site*
Appropriate Use Rating
ss Site Placement*
plex) 3 months prior to access placement R (3)
plex) <3 months prior to access placement A (8)
ature”
er placement M (6)
r placement A (8)
s of Diseasey
s, kt/V, recirculation times, or increased A (8)
A (8)
A (8)
A (8)
cted arterial steal syndrome) A (8)
R (3)
A (8)
ticy
R (3)
rterial and venous duplex examination that is performed to determine the adequacy of superﬁcial
arterial inﬂow. Determination of central venous patency is particularly important for patients with
ialysis.
rosthetic arteriovenous graft; M ¼ maybe appropriate; R ¼ rarely appropriate.
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660renal vein thrombosis, renal vein duplex ultrasound was
rated as maybe appropriate. Renal venous duplex was rated
as rarely appropriate for evaluation of gross or microscopic
hematuria, pulmonary symptoms, or fever of unknown
origin. Renal venous duplex was rated as rarely appropriate
for evaluation of epigastric bruit or drug-resistant hyper-
tension, scenarios for which arterial duplex testing would
be a more appropriate test (1).
Section 5: Hemodialysis Vascular Access
Duplex Ultrasound
Summary: Hemodialysis Vascular Access
Duplex Ultrasound
For vascular assessment (or mapping) prior to the place-
ment of hemodialysis access, duplex ultrasound was rated
as appropriate when performed less than 3 months prior to
the procedure. Vascular assessment prior to access place-
ment was rated as rarely appropriate when performed
earlier than this time, reﬂecting the potential for interval
development of vascular lesions in the hemodialysis patient
(e.g., superﬁcial or deep vein thromboses). Following
dialysis access placement, indications were rated according
to presence and nature of symptoms and time interval
following access placement. For the assessment of access
that has failed to mature on the basis of physical exami-
nation ﬁndings, duplex ultrasound was rated as an appro-
priate test beyond 6 weeks after access placement and
maybe appropriate within 0 to 6 weeks of placement.
Duplex ultrasound was rated as an appropriate test for
most clinical scenarios related to upper extremity symp-
toms in the patient with mature dialysis access, including
mass associated with an autogenous arteriovenous ﬁstula
(AVF)/prosthetic arteriovenous graft (AVG), arm
swelling, or signs of digital ischemia due to steal
phenomenon (hand pallor, pain, or ulceration). Similarly,
duplex ultrasound was rated as an appropriate test for signs
of malfunction and/or occlusion in a mature and previously
functional AVF/AVG, including repeated difﬁculties with
access cannulation, low ﬂow or other signs of malfunction
during dialysis sessions, and loss of palpable thrill over
the access. Evaluation of a cool, but otherwise entirely
asymptomatic, upper extremity with duplex ultrasound was
rated as rarely appropriate. The technical panel rated
routine duplex surveillance of a functional AVF/AVG in
an asymptomatic patient with no signs of access mal-
function as rarely appropriate.
7. Discussion
The noninvasive vascular laboratory plays a central role in
the evaluation and surveillance of peripheral vascular
disorders. The scope of this document includes common
and less common clinical indications encountered among
patients with suspected or known venous disease, the most
common of which being venous thromboembolism (e.g.,DVT, pulmonary embolism, and superﬁcial thrombo-
phlebitis) and chronic venous insufﬁciency, either due to
primary varicose veins or secondary to prior DVT (post-
thrombotic syndrome) or other nonthrombotic venous
pathology (e.g., congenital venous anomaly). Indications
for vascular testing prior to or after placement of hemo-
dialysis access are included in this document, as evaluation
of the superﬁcial, deep, and central veins of the upper
extremity constitutes a large component of these exami-
nations. It is assumed that protocols for assessment prior to
and following hemodialysis access will also include imaging
of the arterial system, as determined by the clinical indi-
cation and type of dialysis access.
Due to the diversity of peripheral vascular disorders, it is
likely that many potential clinical indications are not
included in this document. Rather than an exhaustive
compendium of clinical indications, it is intended that this
document address the most common and important
clinical scenarios encountered in the patient with mani-
festations of peripheral vascular disease. Although this
document largely focuses on ratings for duplex ultrasound,
some common clinical indications for venous physiological
testing were included, recognizing that physiological
testing is used in some clinical centers as a tool for eval-
uation of the patient with lower extremity symptoms
suspicious for venous disease. Importantly, venous physi-
ological testing was rated as rarely appropriate for evalua-
tion of the patient with acute lower extremity swelling and
suspected DVT, for whom venous duplex ultrasound was
rated an appropriate test.
It is intended that this document, along with appro-
priate use criteria for arterial testing published in 2012 (1),
will provide guidance for clinicians in maximizing the
appropriate use of the noninvasive vascular laboratory for
the care of patients with suspected or known peripheral
vascular disorders. In addition, it is intended that this
document identify critical evidence gaps in the ﬁeld and
serve as a reference for policy makers with regard to
noninvasive vascular testing. Although the Part I and Part
II Peripheral Vascular Ultrasound AUC documents share
a common intent, methodology, and structure, there are
important differences to note. In the Part I document, 159
clinical indications related to arterial testing were rated,
including numerous indications which rated timing of
surveillance studies either prior to (e.g., asymptomatic
carotid artery stenosis) or following revascularization (e.g.,
testing for patency and restenosis of lower extremity bypass
grafts and stents). Reﬂecting the more focused spectrum of
pathology in the venous system, as well as fewer distinct
vascular beds to image, this venous testing document
presents ratings for 116 clinical indications. In the venous
document, there are fewer indications related to repeated
testing or surveillance of known disease. Although vascular
testing is commonly repeated for surveillance of arterial
atherosclerotic disease or aneurysms to determine the need
for revascularization or repair (e.g., severe internal carotid
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are far fewer clinical scenarios in which surveillance testing
for venous disease is performed (e.g., for surveillance
of known calf DVT with contraindication to anti-
coagulation). Similarly, unlike the arterial document in
which multiple clinical indications for testing following
surgical or endovascular treatment were rated, the role of
duplex ultrasound for follow-up after venous procedures
(e.g., pharmacomechanical thrombolysis or venous stenting
for DVT) is not as well established. Finally, it is important
to note that the Part II venous testing document incor-
porates clinical indication classiﬁcation terminology that
has been revised since publication of the arterial document
(appropriate care, maybe appropriate care, rarely appro-
priate care).
Summary of Evidence and
Call for Additional Research
The current evidence base and clinical practice guidelines
were used to develop and rate the clinical indications
whenever available, although for a large number of clinical
indications, the available scientiﬁc literature was limited
and clinical consensus or expert opinion played a larger
role. Clinical practice guidelines and additional literature
reviewed are presented in the Online Appendix. Speciﬁ-
cally, with regard to diagnosis of DVT, the writing
committee reviewed recently published guidelines from the
American College of Chest Physicians (ACCP) (8) and
recognized that the ACCP document serves to provide
global diagnostic algorithms for venous thromboembolism
that incorporate pre-test probability assessment, D-dimer
testing, and alternative imaging modalities, the scope of
which is beyond that of this appropriate use document that
focused on venous duplex ultrasound and physiological
testing. In addition, the consensus of the writing
committee, in contrast with that of the ACCP guidelines,
is that the entire lower extremity (whole-leg ultrasound
including the calf veins) should be evaluated in cases of
suspected lower extremity DVT when technically possible.
As was the case for arterial testing, the writing com-
mittee recognizes a need for clinical and cost-effectiveness
studies focused speciﬁcally on noninvasive testing for
venous disease. The writing committee identiﬁes the
following areas as among those in greatest need of focused
research:
1. Comparative clinical and cost effectiveness of various
algorithms for diagnosis of DVT, including pre-test
probability assessment tools (e.g., Wells score), D-
dimer, and venous duplex ultrasound.
2. Comparative clinical and cost effectiveness of clinical
algorithms incorporating venous duplex testing for
the diagnosis of pulmonary embolism.
3. Role of venous duplex ultrasound in clinical algo-
rithms to determine duration of anticoagulation
therapy among patients with unprovoked DVT.4. Comparison of anticoagulation therapy versus
duplex ultrasound surveillance among patients with
isolated calf DVT.
5. Accuracy and clinical beneﬁt of venous duplex ultra-
sound following venous intervention (e.g., pharma-
comechanical thrombolysis, angioplasty, stenting).
6. Optimal timing and utilization of duplex ultrasound
in clinical practice for assessment of dialysis access
maturity.Appendix A: Additional Methods
See the Methods section of the report for a description of
panel selection, indication development, scope of indica-
tions, and rating process.
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